comparemela.com

Latest Breaking News On - க்வ் மருந்துகள் ப்ல் - Page 4 : comparemela.com

Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion

Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion Bloomberg 2/3/2021 Timothy Annett and Tiffany Kary © Bloomberg An employee inspects cannabis plants in a greenhouse in the GW Pharmaceuticals Plc facility in Sittingboune, U.K. on Monday, Oct. 29, 2018. The U.K. is the biggest producer of cannabis for medical and scientific purposes, according to the United Nations. (Bloomberg) Jazz Pharmaceuticals Plc has agreed to acquire GW Pharmaceuticals Plc, maker of the first drug derived from the cannabis plant to win approval in the U.S., for $7.2 billion in cash and stock. Popular Searches The price amounts to a premium of about 50% over Cambridge, England-based GW’s closing price on Tuesday. GW’s U.S.-traded shares gained as much as 49% in Wednesday trading, and Jazz shares declined 3.7%.

Capri, Alphabet rise; Chipotle, Electronic Arts fall

Capri, Alphabet rise; Chipotle, Electronic Arts fall by The Associated Press Last Updated Feb 3, 2021 at 4:28 pm EDT NEW YORK Stocks that traded heavily or had substantial price changes Wednesday: Alphabet Inc., up $139.76 to $2,058.88. The parent company of search engine Google handily beat Wall Street’s fourth-quarter profit and revenue forecasts. Chipotle Mexican Grill Inc., down $23.06 to $1,499.99. The Mexican food chain’s fourth-quarter profit fell short of analysts’ forecasts. Amazon.com Inc., down $67.47 to $3,312.53. Jeff Bezos will step down as CEO of the the online retail giant, to be replaced by long-time executive Andy Jassy. Electronic Arts Inc., down $8.15 to $140.82. The maker of “Medal of Honor” and other video games gave investors a disappointing profit forecast.

Jazz Pharmaceuticals to Buy Pot-Drug Maker for $7.2 Billion

Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion Bloomberg 2/3/2021 Timothy Annett and Tiffany Kary © Bloomberg An employee inspects cannabis plants in a greenhouse in the GW Pharmaceuticals Plc facility in Sittingboune, U.K. on Monday, Oct. 29, 2018. The U.K. is the biggest producer of cannabis for medical and scientific purposes, according to the United Nations. (Bloomberg) Jazz Pharmaceuticals Plc has agreed to acquire GW Pharmaceuticals Plc, maker of the first drug derived from the cannabis plant to win approval in the U.S., for $7.2 billion in cash and stock. Popular Searches The price amounts to a premium of about 50% over Cambridge, England-based GW’s closing price on Tuesday. GW’s U.S.-traded shares gained as much as 49% in Wednesday trading, and Jazz shares declined 3.7%.

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals

Source: Streetwise Reports  (2/3/21) Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share. Biopharmaceutical firm GW Pharmaceuticals Plc (GWPH:NASDAQ), which utilizes its proprietary cannabinoid product platform to develop and commercialize new medicines across a broad range of disease areas, and global biopharmaceutical company Jazz Pharmaceuticals Plc (JAZZ:NASDAQ), announced that the companies have entered into a definitive agreement for Jazz Pharmaceuticals to acquire GW Pharmaceuticals. The companies stated that the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.

Medical Marijuana Market Regional Outlook, Share Value, Dynamics, Future Growth, Trends Analysis and Research Overview By 2023

Medical Marijuana Market Regional Outlook, Share Value, Dynamics, Future Growth, Trends Analysis and Research Overview By 2023
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.